NanoKnife Technology Expands European Indications for Tumor Treatment

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 19 2026

0mins

ANGO+1.95%

Should l Buy ANGO?

Source: Newsfilter

Indication Expansion: AngioDynamics announced expanded indications for its NanoKnife System in Europe, including soft tissue ablation for liver, pancreas, kidney, and prostate tumors, particularly benefiting intermediate-risk prostate cancer patients, which significantly enhances physician access and is expected to drive market share growth in cancer treatment.
Technological Advantage: The NanoKnife System utilizes irreversible electroporation (IRE) technology to effectively destroy tumor cells without damaging critical surrounding anatomy, making it particularly advantageous for tumors in complex anatomical regions, thereby reinforcing its competitive position in the market.
Growing Clinical Evidence: A growing body of prospective and multicenter studies supports the use of IRE technology across multiple solid tumor indications, leading to increased physician adoption in Europe and globally, with annual IRE procedures estimated to exceed 45,000, reflecting rising cancer incidence and strong demand for minimally invasive treatment options.
Global Registry Initiative: AngioDynamics will initiate the LIVER-IRE Global Registry in collaboration with Professor Ajith Siriwardena at the University of Manchester, designed to prospectively evaluate outcomes in patients undergoing IRE treatment for liver tumors, further contributing to the growing body of real-world clinical data supporting multi-organ applications of the NanoKnife System technology.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ANGO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ANGO

Wall Street analysts forecast ANGO stock price to rise

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 10.780

Low

16.00

Averages

19.33

High

24.00

Current: 10.780

Low

16.00

Averages

19.33

High

24.00

Canaccord

John Young

Buy

maintain

$15 -> $17

2025-07-16

Reason

Canaccord

John Young

Price Target

$15 -> $17

AI Analysis

2025-07-16

maintain

Buy

Reason

Canaccord analyst John Young raised the firm's price target on AngioDynamics to $17 from $15 and keeps a Buy rating on the shares. The firm said the company had another well-executed quarter, driven by growth in its Med-Tech business with nice beats across the board. Med-Tech, Med-Device, total revenues, adj. EBITDA and adj. EPS all beat estimates, capping off a momentum-building year for the company and there wasn't much thesis changing news for the company during the quarter.

Lake Street

Buy

initiated

$24

2025-07-16

Reason

Lake Street

Price Target

$24

2025-07-16

initiated

Buy

Reason

Lake Street initiated coverage of AngioDynamics with a Buy rating and $24 price target. The firm says the company has transformed its portfolio into faster-growth and higher-margin cardiovascular and cancer treatment products. The Street is missing AngioDynamics' strategic realignment as the shares should be valued more in line with higher multiple medical technology companies, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANGO

Unlock Now

About ANGO

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Bastion Asset Management Acquires Stake in Parsons

Feb 27 2026Fool

New Investment Position: Bastion Asset Management disclosed a new position in Parsons by acquiring 128,186 shares in Q4 2025, with an estimated transaction value of $8.04 million, indicating a strategic focus on defense and infrastructure sectors.
Significant Holding Proportion: Following this transaction, Parsons represents 4.44% of Bastion's $181.13 million reportable U.S. equity assets, highlighting its importance in the portfolio and the firm's preference for stable cash flow investments.
Market Performance Analysis: As of February 5, 2026, Parsons shares were priced at $67.52, reflecting a 13% decline over the past year and underperforming the S&P 500 by 25.12 percentage points, suggesting market caution regarding its future growth prospects.
Diversified Business Advantage: Parsons operates a dual-segment model in defense and infrastructure, ensuring that when defense spending contracts, infrastructure projects can compensate for revenue shortfalls, demonstrating resilience amid economic fluctuations.

Bastion Asset Management Acquires $8M Stake in Parsons

Feb 27 2026Yahoo Finance

New Position Disclosure: On February 6, 2026, Bastion Asset Management disclosed a new position in Parsons (NYSE:PSN), acquiring 128,186 shares valued at approximately $8.04 million, indicating a strategic interest in defense and infrastructure sectors.
Holding Proportion Analysis: Following this transaction, Parsons represents 4.44% of Bastion's portfolio, which totaled $181.13 million in reportable U.S. equity assets as of December 31, 2025, reflecting Bastion's preference for stable income investments.
Market Performance Overview: As of February 5, 2026, Parsons shares were priced at $67.52, down 13% year-over-year, underperforming the S&P 500 by 25.12 percentage points, indicating market caution regarding its future growth prospects.
Business Diversification: Parsons generates revenue from various sectors, particularly through contracts with the Pentagon, demonstrating its ability to maintain stable cash flow amidst economic fluctuations, making it suitable for investors seeking steady returns.

AngioDynamics to Present at Global Healthcare Conference

Feb 23 2026Newsfilter

Presentation Schedule: Jim Clemmer, President and CEO of AngioDynamics, will present at the Leerink Partners Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET, highlighting the company's advancements in medical technology.
Live Webcast Availability: The presentation will be accessible via a live webcast on the company's website under the 'Investors' section, with a replay available post-event, ensuring timely access to information for investors and the public.
Company Background: AngioDynamics focuses on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life, with its innovative technologies and devices favored by physicians in rapidly growing healthcare markets to address unmet patient needs.
Media Contact Information: For further inquiries, investors can reach out to CFO Stephen Trowbridge, while media can contact Vice President Saleem Cheeks, ensuring transparency and timely dissemination of information.